Palladyne AI and IAI: the loitering-munitions exclusive is still a memorandum

On 8 June 2026 a press release runs the headline: “Palladyne AI and IAI Form Partnership to Manufacture and Sell Combat-Proven Loitering Munition Systems to the U.S. Department of War.” The filing that accompanies it at the SEC calls the same thing by a different name: not a contract, but “a memorandum of understanding” — “subject to the parties entering into a more extensive definitive implementation agreement” still to be negotiated. The difference between the two versions is not cosmetic: it bears on who has a right to what, for how long, and which carve-outs are already written into the text.

The facts, from the filing

The Form 8-K filed on 8 June 2026 (accession 0001193125-26-260664) by Palladyne AI Corp. (NASDAQ: PDYN/PDYNW) covers Items 7.01 (Regulation FD) and 8.01 (Other Events). Item 8.01 describes the arrangement precisely: “the Company announced that it has entered into a memorandum of understanding (the ‘MOU’) with Israel Aerospace Industries Ltd., acting through its MBT Missiles Division, Systems, Missiles & Space Group (‘IAI’).” A sentence follows that rarely appears in a corporate filing: “IAI is wholly owned by the government of Israel.” That is not colour: it is the counterparty itself, stated in black and white by Palladyne.

The MOU covers HARPY, HAROP and Mini-HARPY, loitering munitions designed to find and strike enemy radars, launchers and command posts (a SEAD/DEAD mission). Palladyne gets “the exclusive right to manufacture and market to the U.S. government” those systems, with no upfront payment, only “a market-rate royalty equal to a percentage of sales” that is not disclosed, for “up to ten years” conditioned on undisclosed milestones. One sentence, though, does most of the work of qualifying that adjective: “nothing in the MOU precludes the government of Israel from selling Systems directly to the U.S. government.” The exclusive binds Palladyne’s own commercial conduct — it will not sell competing systems — not the sovereign seller’s freedom to reach the same customer by another route. The supply of subsystems from IAI is likewise “subject to approval of the United States Government and to the extent permitted by United States law.” Two sovereignty reservations, one Israeli and one American, frame a deal presented as “exclusive.” To keep the rights, Palladyne must also build a US assembly line at its own cost.

What the filing does not contain

No Item 1.01 — “Entry into a Material Definitive Agreement” — accompanies this announcement, neither the 8 June 8-K nor the one filed on 6 August 2026 (accession 0001193125-26-336621), where second-quarter results list the IAI deal first among the “Strategic and Operational Highlights”: “Signed an exclusive partnership with IAI (…) with no upfront payment and up to ten years of exclusivity.” Since 2021, Palladyne has used Item 1.01 six times — most recently on 31 October 2024 — but always for corporate finance: share placements, and the 2021 agreement that turned the SPAC Rotor Acquisition Corp. into Sarcos Technology & Robotics Corp. (renamed Palladyne AI in March 2024). Never for a commercial agreement with a supplier. That is consistent with the filing’s own text, which frames the MOU as preliminary to an implementation agreement still to be signed — but it is a distinction the press release does not flag.

Who the two parties are

Palladyne AI began as Sarcos, artificial-intelligence software for robotics; it only started manufacturing hardware “with a series of acquisitions last fall,” autumn 2025, according to what CEO Ben Wolff told Breaking Defense. The quarter ended 30 June 2026 shows revenue of $5.8 million (up 470% year on year) against an operating loss of $13.4 million: real growth, still on a small base. Wolff told Breaking Defense that IAI’s first reaction, when Palladyne proposed licence-building the Harpy family, was reportedly: “you’re an AI company — what do you know about manufacturing?” Israel Aerospace Industries, for its part, has built loitering munitions for more than forty years; Harpy locates enemy radars without needing prior target coordinates. The Jerusalem Post writes that the systems “have seen recent battlefield use by Azerbaijan and India” — a claim reported by a third party, which we have not independently verified. IAI chief executive Boaz Levy stated that the deal “represents a significant step in expanding our long-term presence and industrial cooperation in the U.S. defense sector.”

What we do not know

We do not know the royalty percentage, nor the “certain milestones” that condition the ten years of exclusivity. We do not know whether the intellectual-property licence described in Item 8.01 is already operative or remains suspended until the definitive implementation agreement is signed: the text (“subject to… IAI has granted”) supports either reading, and no source resolves it. We do not know whether Israel’s own arms-export control authority has already cleared the arrangement, nor whether the ITAR licences (Arms Export Control Act, administered by the State Department’s Directorate of Defense Trade Controls) needed for the technology transfers have even been sought. We do not know, as of writing, whether that definitive implementation agreement has been signed: in the 6 August 8-K, seven weeks after the announcement, Wolff still speaks of “strategy and planning,” not of a second filing. And the Army’s Long Range Precision Munitions competition — a prototype award of $100–200 million expected in October 2026, according to Breaking Defense — remains an open solicitation, not a contract awarded to this pairing of companies.

Why it matters, for whoever drafts a tender

The lesson is not about the legitimacy of the deal — an MOU is by nature a preliminary understanding, and neither party claims otherwise. It is about the word “exclusive,” which trade press coverage repeats without the two reservations the filing itself carries: a sovereign seller can bypass its own licensee, and component supply stays conditioned on a third government’s approval. It is the same check that applies when reading the memorandum between IonQ and Anduril or the arrangement between NextNav and Safran: an adjective in a press release does not by itself settle who may sell what to whom. For a defence procurement office assessing a supplier on a capability described as “exclusive,” the job is to read the filing’s text, not the release’s headline — and to ask in writing whether the definitive implementation agreement has been signed before treating the capability as secured.

The two axes, applied

Comply. The register of critical suppliers of defence capabilities stops being press releases read once: it becomes a check that runs over suppliers’ public filings and contracts — which document was actually signed, which sovereignty reservations remain written into the text, which third-government approvals condition each supply — with a dated trail, ready for an inspection or a board.

Decide. The same system holds contracts, releases, public filings and suppliers’ technical documents together in a single operating model, on which AI agents execute decisions with a human operator in command — for large enterprises, defence, public administration and healthcare. Always in two modes: on-premises, on autonomous machines with no deep integration into the client’s network, or a dedicated cloud with a dedicated VPN and a data centre in Italy, always with shared management: no one is left alone administering a system that has to trust an exclusive declared by someone else.

From the first session, at no cost, you get a dated list of the critical capabilities you buy from foreign suppliers — which document actually governs each one, which sovereignty reservations remain written in, which approvals are still missing: it stays yours even if we do not go on to work together. Talk to one of our engineers.